Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Oscier

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|April 15, 2014
The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptorsJitka Malcikova, Evangelia Stalika, Zadie Davis, et al.
Clinical Epigenetics|December 4, 2019
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapyMaria Tsagiopoulou, Nikos Papakonstantinou, Theodoros Moysiadis, et al.
British Journal of Haematology|July 24, 2012
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphomaVicente Fresquet, Eloy F Robles, Anton Parker, et al.
Blood|March 23, 2010
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsAmy V Jones, Peter J Campbell, Philip A Beer, et al.
Haematologica|August 2, 2016
ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeresVeronika Navrkalova, Emma Young, Panagiotis Baliakas, et al.
Haematologica|April 5, 2015
Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidantsAngelo Agathanggelou, Victoria J Weston, Tracey Perry, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
Gene|November 26, 2003
Distinct organization of the candidate tumor suppressor gene RFP2 in human and mouse: multiple mRNA isoforms in both species- and human-specific antisense transcript RFP2OSAncha Baranova, Marianne Hammarsund, Dmitry Ivanov, et al.
Blood|May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersAmy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|April 15, 2014
The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptorsJitka Malcikova, Evangelia Stalika, Zadie Davis, et al.
Clinical Epigenetics|December 4, 2019
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapyMaria Tsagiopoulou, Nikos Papakonstantinou, Theodoros Moysiadis, et al.
British Journal of Haematology|July 24, 2012
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphomaVicente Fresquet, Eloy F Robles, Anton Parker, et al.
Blood|March 23, 2010
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsAmy V Jones, Peter J Campbell, Philip A Beer, et al.
Haematologica|August 2, 2016
ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeresVeronika Navrkalova, Emma Young, Panagiotis Baliakas, et al.
Haematologica|April 5, 2015
Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidantsAngelo Agathanggelou, Victoria J Weston, Tracey Perry, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
Gene|November 26, 2003
Distinct organization of the candidate tumor suppressor gene RFP2 in human and mouse: multiple mRNA isoforms in both species- and human-specific antisense transcript RFP2OSAncha Baranova, Marianne Hammarsund, Dmitry Ivanov, et al.
Blood|May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersAmy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Pageof 10